How does a blood disorder drug perform in everyday practice?

NCT ID NCT07681440

Terminated Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study looks at how the drug luspatercept is used in real-world clinics for patients with lower-risk myelodysplastic syndromes (MDS) or beta-thalassemia. Researchers will track patient characteristics, treatments, and outcomes like reduced need for blood transfusions. The goal is to understand the drug's effectiveness and costs outside of strict clinical trial settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: luspatercept
What this could lead to: If successful, this could help doctors understand how luspatercept works outside of clinical trials, potentially improving treatment guidelines for these blood disorders.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be limited by small size and real-world data variability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

beta thalassemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BETA-THALASSEMIA MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

ZEG Berlin, Center for Epidemiology and Health Research

Berlin, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.